KRAS and non-small cell lung carcinoma: Lung tumors, mainly non-small cell lung cancer (NSCLC), showed robust CD73 expression signatures among all cancer types, particularly when associated with common oncogenic drivers of NSCLC, such as mutant epidermal growth factor receptor (EGFR) and KRAS [18,19].